Skip to content

Study · Other design · 2023

6 results

Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.

Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y

Molecules (Basel, Switzerland)30 Oct 2023Cited by 3 (Europe PMC)

PMID37959764 (opens in a new tab)PMCIDPMC10650108 (opens in a new tab)DOI10.3390/molecules28217345 (opens in a new tab)PepBankPUB-37959764
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Traditional strategies for the metabolic profiling of doping are limited by the unpredictable metabolic pathways and the numerous proportions of background and chemical noise that lead to inadequate metabolism knowledge, thereby affecting the selection of optimal detection targets. Thus, a stable isotope labeling-based nontargeted strategy combined with ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) was first proposed for the effective and rapid metabolism analysis of small-molecule doping agents and demonstrated via its application to a novel doping BPC-157. Using 13C/15N-labeled BPC-157, a complete workflow including automatic 13C0,15N0-13C6,15N2m/z pair picking based on the characteristic behaviors of isotope pairs was constructed, and one metabolite produced by a novel metabolic pathway plus eight metabolites produced by the conventional amide-bond breaking metabolic pathway were successfully discovered from two incubation models. Furthermore, a specific method for the detection of BPC-157 and the five main metabolites in human urine was developed and validated with satisfactory detection limits (0.01~0.11 ng/mL) and excellent quantitative ability (linearity: 0.02~50 ng/mL with R2 > 0.999; relative error (RE)% < 10% and relative standard deviation (RSD)% < 5%; recovery > 90%). The novel metabolic pathway and the in vitro metabolic profile could provide new insights into the biotransformation of BPC-157 and improved targets for doping control.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabOther designPharmacokinetics

    In two in vitro incubation models, labeled BPC‑157 gave one metabolite from a novel metabolic pathway and eight metabolites from the conventional amide-bond breaking pathway.

    In plain wordsIn lab tests, BPC‑157 broke down into several products, one of them by a new pathway.

    Peptide
    BPC-157
    Outcome
    Not applicableIn vitro metabolites of BPC-157
    Study

    n: not reported in source

    in vitro incubation models
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    one metabolite produced by a novel metabolic pathway plus eight metabolites produced by the conventional amide-bond breaking metabolic pathway were successfully discovered from two incubation models

Studies that did not test the peptide alone5

In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking BPC-157.

  1. 02LabNot a test of BPC-157 aloneOther designOther

    A UHPLC-HRMS method for BPC‑157 and its five main metabolites in human urine had detection limits of 0.01 to 0.11 ng/mL.

    In plain wordsIn lab tests, a new urine test could detect very small amounts of BPC‑157 and its breakdown products.

    Peptide
    BPC-157
    Outcome
    Not applicableDetection limits of the urine method for BPC-157 and five main metabolites
    Study

    n: not reported in source

    human urine
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Limit of detection
    0.01 to 0.11 ng/mL
    BPC-157 and five main metabolites in human urine

    Source sentences

    Summary
    a specific method for the detection of BPC-157 and the five main metabolites in human urine was developed and validated with satisfactory detection limits (0.01~0.11 ng/mL)

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  2. 03LabNot a test of BPC-157 aloneOther designOther

    The urine method for BPC‑157 and its five main metabolites was linear from 0.02 to 50 ng/mL with R2 above 0.999.

    In plain wordsIn lab tests, the urine test for BPC‑157 gave results that scaled steadily across a wide range of amounts.

    Peptide
    BPC-157
    Outcome
    Not applicableLinearity of the urine method
    Study

    n: not reported in source

    human urine
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Linear range
    0.02 to 50 ng/mL
    human urine method
    R2
    > 0.999
    human urine method

    Source sentences

    Summary
    linearity: 0.02~50 ng/mL with R2 > 0.999

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  3. 04LabNot a test of BPC-157 aloneOther designOther

    The urine method for BPC‑157 and its five main metabolites had a relative error below 10%.

    In plain wordsIn lab tests, the urine test for BPC‑157 was accurate, with an error below 10%.

    Peptide
    BPC-157
    Outcome
    Not applicableRelative error of the urine method
    Study

    n: not reported in source

    human urine
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Relative error
    < 10%
    human urine method

    Source sentences

    Summary
    relative error (RE)% < 10%

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  4. 05LabNot a test of BPC-157 aloneOther designOther

    The urine method for BPC‑157 and its five main metabolites had a relative standard deviation below 5%.

    In plain wordsIn lab tests, the urine test for BPC‑157 gave repeatable results, with a spread below 5%.

    Peptide
    BPC-157
    Outcome
    Not applicableRelative standard deviation of the urine method
    Study

    n: not reported in source

    human urine
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Relative standard deviation
    < 5%
    human urine method

    Source sentences

    Summary
    relative standard deviation (RSD)% < 5%

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  5. 06LabNot a test of BPC-157 aloneOther designOther

    The urine method for BPC‑157 and its five main metabolites had a recovery above 90%.

    In plain wordsIn lab tests, the urine test for BPC‑157 recovered more than 90% of the amount present.

    Peptide
    BPC-157
    Outcome
    Not applicableRecovery of the urine method
    Study

    n: not reported in source

    human urine
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Recovery
    > 90%
    human urine method

    Source sentences

    Summary
    recovery > 90%).

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.